0001209191-22-008937.txt : 20220211 0001209191-22-008937.hdr.sgml : 20220211 20220211172633 ACCESSION NUMBER: 0001209191-22-008937 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220210 FILED AS OF DATE: 20220211 DATE AS OF CHANGE: 20220211 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: King Andrew James CENTRAL INDEX KEY: 0001823187 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37345 FILM NUMBER: 22622918 MAIL ADDRESS: STREET 1: C/O CHINOOK THERAPEUTICS U.S., INC. STREET 2: 1600 FAIRVIEW AVE. E. CITY: SEATTLE STATE: WA ZIP: 98102 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CHINOOK THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001435049 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 400 FAIRVIEW AVENUE NORTH, SUITE 900 CITY: SEATTLE STATE: WA ZIP: 98109 BUSINESS PHONE: 206-485-7051 MAIL ADDRESS: STREET 1: 400 FAIRVIEW AVENUE NORTH, SUITE 900 CITY: SEATTLE STATE: WA ZIP: 98109 FORMER COMPANY: FORMER CONFORMED NAME: ADURO BIOTECH, INC. DATE OF NAME CHANGE: 20111107 FORMER COMPANY: FORMER CONFORMED NAME: ADURO BIOTECH DATE OF NAME CHANGE: 20080514 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-02-10 0 0001435049 CHINOOK THERAPEUTICS, INC. KDNY 0001823187 King Andrew James C/O CHINOOK THERAPEUTICS, INC. 400 FAIRVIEW AVE. NO., 9TH FLOOR SEATTLE WA 98102 0 1 0 0 Chief Scientific Officer Common Stock 2022-02-10 4 M 0 2500 0.35 A 6594 D Common Stock 2022-02-10 4 S 0 2500 13.31 D 4094 D Stock Option (right to buy) 0.35 2022-02-10 4 M 0 2500 0.00 D 2029-06-05 Common Stock 2500 68047 D The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. The stock option vested as to 25% of the total shares on May 6, 2020, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date. /s/ Kirk Schumacher, Attorney-in-Fact 2022-02-11